TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Average Recommendation of “Moderate Buy” by Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $9.00.

HURA has been the topic of several recent research reports. Citigroup initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price objective on the stock. Finally, Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in shares of TuHURA Biosciences by 24.0% in the first quarter. Bank of America Corp DE now owns 78,142 shares of the company’s stock worth $140,000 after buying an additional 15,135 shares during the period. Greenline Wealth Management LLC acquired a new position in shares of TuHURA Biosciences in the first quarter worth about $66,000. Merck & Co. Inc. boosted its holdings in shares of TuHURA Biosciences by 39.4% in the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock worth $35,000 after buying an additional 5,495 shares during the period. Cetera Investment Advisers acquired a new position in shares of TuHURA Biosciences in the first quarter worth about $251,000. Finally, WealthShield Partners LLC acquired a new position in shares of TuHURA Biosciences in the first quarter worth about $164,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Price Performance

Shares of HURA opened at $2.12 on Thursday. The firm’s 50 day moving average is $2.27 and its 200-day moving average is $1.60. The stock has a market capitalization of $135.00 million, a P/E ratio of -3.48 and a beta of 0.01. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities research analysts forecast that TuHURA Biosciences will post -0.56 EPS for the current fiscal year.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.